Episode 235: Daniel Heng, MD, on IMDC Classification in RCC

Daniel Heng, MD, MPH, FRCPC, joins us to discuss IMDC classification for renal cell carcinoma and the treatment of patients with favorable risk disease.
Dr. Heng is a professor of oncology at the University of Calgary in Alberta, Canada, and is the leader of the International mRCC Database Consortium (IMDC) which consists of data from over 9,200 patients with mRCC treated with targeted therapies from over 38 cancer centers worldwide.